GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...
GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...
Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...
AstraZeneca breached the UK pharmaceutical industry's code of practice after a website claim incorrectly stated that all ...
The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the ...
GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth indication. The drug is now cleared to treat certain patients with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback